α-Tocopheryloxyacetic acid: A novel chemotherapeutic that stimulates the antitumor immune response

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Hahn, Tobias ^a   Jagadish, Bhumasamudram ^b   Mash, Eugene A ^b   Garrison, Kendra ^a   Akporiaye, Emmanuel T ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHERYLOXYACETIC ACID; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 4; UNCLASSIFIED DRUG; 2,5,7,8 TETRAMETHYL 2R (4R,8R,12 TRIMETHYLTRIDECYL)CHROMAN 6 YLOXY ACETIC ACID; 2,5,7,8-TETRAMETHYL-2R-(4R,8R,12-TRIMETHYLTRIDECYL)CHROMAN-6-YLOXY ACETIC ACID; CYTOKINE; TOCOPHEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECT; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE; LYMPHOCYTE ACTIVATION; METABOLISM; ORAL DRUG ADMINISTRATION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TOCOPHEROLS; TUMOR MICROENVIRONMENT;

EID: 84860390351     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2808     Document Type: Article

References (73)

1. Wang XF, Dong L, Zhao Y, Tomasetti M, Wu K, Neuzil J. Vitamin E analogues as anticancer agents: lessons from studies with α-tocopheryl succinate. Mol Nutr Food Res 2006, 50:675-685. 10.1002/mnfr.200500267, 16835868.
2. Kline K, Lawson KA, Yu W, Sanders BG. Vitamin E and cancer. Vitam Horm 2007, 76:435-461. 10.1016/S0083-6729(07)76017-X, 17628185.
3. Neuzil J, Dong LF, Ramanathapuram L, Hahn T, Chladova M, Wang XF, Zobalova R, Prochazka L, Gold M, Freeman R, Turanek J, Akporiaye ET, Dyason JC, Ralph SJ. Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria. Mol Aspects Med 2007, 28:607-645. 10.1016/j.mam.2007.02.003, 17499351.
4. Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K. Pro-apoptotic mechanisms of action of a novel vitamin E analog (α-TEA) and a naturally occurring form of vitamin E (δ-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer 2004, 48:95-105. 10.1207/s15327914nc4801_13, 15203383.
5. Lawson KA, Anderson K, Simmons-Menchaca M, Atkinson J, Sun L, Sanders BG, Kline K. Comparison of vitamin E derivatives α-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp Biol Med (Maywood) 2004, 229:954-963.
6. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. α-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med (Maywood) 2004, 229:1169-1176.
7. Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2003, 2:437-444.
8. Riedel SB, Fischer SM, Sanders BG, Kline K. Vitamin E analog, α-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice. Anticancer Drugs 2008, 19:175-181. 10.1097/CAD.0b013e3282f28ffb, 18176114.
9. Hahn T, Szabo L, Gold M, Ramanathapuram L, Hurley LH, Akporiaye ET. Dietary administration of the proapoptotic vitamin E analogue α-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res 2006, 66:9374-9378. 10.1158/0008-5472.CAN-06-2403, 17018590.
10. Neuzil J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity. Br J Cancer 2003, 89:1822-1826. 10.1038/sj.bjc.6601360, 2394445, 14612885.
11. Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by α-tocopheryl succinate. Br J Cancer 2001, 84:87-89. 10.1054/bjoc.2000.1559, 2363620, 11139318.
12. Lawson KA, Anderson K, Snyder RM, Simmons-Menchaca M, Atkinson J, Sun LZ, Bandyopadhyay A, Knight V, Gilbert BE, Sanders BG, Kline K. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004, 54:421-431. 10.1007/s00280-004-0817-y, 15197487.
13. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004, 64:4919-4926. 10.1158/0008-5472.CAN-04-0884, 15256464.
14. Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue, α-TEA. Cancer Res 2004, 64:4263-4269. 10.1158/0008-5472.CAN-03-2327, 15205340.
15. Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery 2002, 131:85-91. 10.1067/msy.2002.119191, 11812968.
16. Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 1999, 33:26-32. 10.1080/01635589909514744, 10227040.
17. Ramanathapuram LV, Hahn T, Graner MW, Katsanis E, Akporiaye ET. Vesiculated α-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunol Immunother 2006, 55:166-177. 10.1007/s00262-005-0016-7, 16041582.
18. Hahn T, Fried K, Hurley LH, Akporiaye ET. Orally active α-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol Cancer Ther 2009, 8:1570-1578. 10.1158/1535-7163.MCT-08-1079, 19509249.
19. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 2008, 14:141-151. 10.1016/j.molmed.2008.02.002, 18353726.
20. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13:54-61. 10.1038/nm1523, 17187072.
21. Lake RA, Robinson BW. Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 2005, 5:397-405. 10.1038/nrc1613, 15864281.
22. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007, 56:1597-1604. 10.1007/s00262-007-0305-4, 17440723.
23. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73. 10.1038/nri2216, 18097448.
24. Kline K, Yu W, Sanders BG. Vitamin E: mechanisms of action as tumor cell growth inhibitors. J Nutr 2001, 131:161S-163S.
25. Neuzil J, Tomasetti M, Mellick AS, Alleva R, Salvatore BA, Birringer M, Fariss MW. Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr Cancer Drug Targets 2004, 4:355-372. 10.2174/1568009043332943, 15180501.
26. Ramanathapuram LV, Kobie JJ, Bearss D, Payne CM, Trevor KT, Akporiaye ET. α-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. Cancer Immunol Immunother 2004, 53:580-588. 10.1007/s00262-004-0499-7, 14991239.
27. Ramanathapuram LV, Hahn T, Dial SM, Akporiaye ET. Chemo-immunotherapy of breast cancer using vesiculated α-tocopheryl succinate in combination with dendritic cell vaccination. Nutr Cancer 2005, 53:177-193. 10.1207/s15327914nc5302_7, 16573379.
28. Kline K, Sanders BG, Hurley L, Gardner R, Menchaca M, Yu W, Ramanan PN, Liu S, Israel K. Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives for use as antitumor agents and for inducing cell apoptosis. PCT Int Appl (Patent number WO/2000/16772).
29. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-β signaling. Int J Cancer 2001, 91:76-82. 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8, 11149423.
30. Miller FR, Heppner GH. Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. J Natl Cancer Inst 1979, 63:1457-1463.
31. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001, Chapter 20. Unit 20.2..
32. Murphy GP, Hrushesky WJ. A murine renal cell carcinoma. J Natl Cancer Inst 1973, 50:1013-1025.
33. Akporiaye ET, Bradley-Dunlop D, Gendler SJ, Mukherjee P, Madsen CS, Hahn T, Besselsen DG, Dial SM, Cui H, Trevor K. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine 2007, 25:6965-6974. 10.1016/j.vaccine.2007.06.063, 2364598, 17707958.
34. Neuzil J. α-Tocopheryl succinate epitomizes a compound with a shift in biological activity due to pro-vitamin-to-vitamin conversion. Biochem Biophys Res Commun 2002, 293:1309-1313. 10.1016/S0006-291X(02)00358-3, 12054655.
35. Yang Q, Goding SR, Hokland ME, Basse PH. Antitumor activity of NK cells. Immunol Res 2006, 36:13-25. 10.1385/IR:36:1:13, 17337762.
36. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009, 27:1746-1752. 10.1200/JCO.2008.17.9036, 19255331.
37. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949. 10.1038/nm1093, 15322536.
38. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006, 16:115-123. 10.1016/j.semcancer.2005.11.005, 16376102.
39. Bui JD, Uppaluri R, Hsieh CS, Schreiber RD. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 2006, 66:7301-7309. 10.1158/0008-5472.CAN-06-0556, 16849580.
40. Young MR, Newby M, Wepsic HT. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res 1987, 47:100-105.
41. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606-612.
42. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006, 24:1169-1177. 10.1200/JCO.2005.03.6830, 16505437.
43. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169:2756-2761.
44. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213. 10.1056/NEJMoa020177, 12529460.
45. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007, 25:2586-2593. 10.1200/JCO.2006.09.4565, 17577038.
46. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102:18538-18543. 10.1073/pnas.0509182102, 1311741, 16344461.
47. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4+ T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368. 10.1084/jem.188.12.2357, 2212434, 9858522.
48. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Köhler G, Young IG, Matthaei KI. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24. 10.1016/S1074-7613(00)80294-0, 8574848.
49. Hsiao YW, Liao KW, Hung SW, Chu RM. Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-β1 and restores the lymphokine-activated killing activity. J Immunol 2004, 172:1508-1514.
50. Padua D, Massague J. Roles of TGFβ in metastasis. Cell Res 2009, 19:89-102. 10.1038/cr.2008.316, 19050696.
51. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995, 222:155-162. 10.1097/00000658-199508000-00007, 1234773, 7543740.
52. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003, 63:1860-1864.
53. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol 2010, 10:554-567. 10.1038/nri2808, 20616810.
54. Kobie JJ, Akporiaye ET. Immunosuppressive role of transforming growth factor β in breast cancer. Clin Appl Immunol Rev 2003, 3:277-287.
55. DuPre SA, Redelman D, Hunter KW. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007, 88:351-360. 10.1111/j.1365-2613.2007.00539.x, 17877537.
56. Lavergne E, Combadière C, Iga M, Boissonnas A, Bonduelle O, Maho M, Debré P, Combadière B. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 2004, 173:3755-3762.
57. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996, 7:1545-1553. 10.1089/hum.1996.7.13-1545, 8864755.
58. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000, 49:181-185. 10.1007/s002620000122, 10941900.
59. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010, 16:4583-4594. 10.1158/1078-0432.CCR-10-0733, 20702612.
60. Maccubbin DL, Wing KR, Mace KF, Ho RL, Ehrke MJ, Mihich E. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992, 52:3572-3576.
61. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007, 109:4839-4845. 10.1182/blood-2006-10-054221, 1885516, 17299090.
62. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059. 10.1038/nm1622, 17704786.
63. Van der Most RG, Currie AJ, Robinson BW, Lake RA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ 2008, 15:13-20. 10.1038/sj.cdd.4402255, 18007666.
64. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 2002, 100:4108-4115. 10.1182/blood-2002-05-1389, 12393401.
65. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002, 20:395-425. 10.1146/annurev.immunol.20.100301.064801, 11861608.
66. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int Immunol 2000, 12:1539-1546. 10.1093/intimm/12.11.1539, 11058573.
67. Bethke K, Staib F, Distler M, Schmitt U, Jonuleit H, Enk AH, Galle PR, Heike M. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 2002, 169:6141-6148.
68. Flohé SB, Brüggemann J, Lendemans S, Nikulina M, Meierhoff G, Flohé S, Kolb H. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 2003, 170:2340-2348.
69. Basu S, Srivastava PK. Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int Immunol 2003, 15:1053-1061. 10.1093/intimm/dxg104, 12917257.
70. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23:2907-2918. 10.1038/sj.onc.1207529, 15077153.
71. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003, 170:4905-4913.
72. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004, 173:5923-5928.
73. Hahn T, Polanczyk MJ, Borodovsky A, Ramanathapuram LV, Akporiaye ET, Ralph SJ. Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. Curr Pharm Biotechnol 2011,